<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247855</url>
  </required_header>
  <id_info>
    <org_study_id>17200098</org_study_id>
    <nct_id>NCT03247855</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Multivessel Minimally Invasive Coronary Artery Bypass Graft Surgery</brief_title>
  <official_title>Safety and Efficacy of Multivessel Minimally Invasive Coronary Artery Bypass Graft Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohammed Farouk Abdel Hafez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of this study is to evaluate safety and efficacy of multivessel minimally invasive&#xD;
      coronary artery bypass graft surgery through evaluating the possibility of reaching complete&#xD;
      revascularization , the complications during surgery and the outcomes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Minimally invasive direct coronary artery bypass (MIDCAB) grafting can achieve adequate&#xD;
      coronary artery revascularization in a less invasive manner than conventional coronary artery&#xD;
      bypass grafting (CABG). Bypass from the internal mammary artery (IMA) to the left anterior&#xD;
      descending coronary artery (LAD) is an effective technique for the treatment of simple&#xD;
      anterior descending artery disease. This surgery is especially recommended for patients with&#xD;
      multiple lesions that are not suitable for stent stenosis . One of the main advantages of&#xD;
      MIDCAB is that there is no need for cardiac arrest and cardiopulmonary bypass (CPB) transfer&#xD;
      during surgery . MIDCAB patients also benefit from the neurological protection associated&#xD;
      with this minimally invasive procedure . Unlike traditional revascularization techniques,&#xD;
      which are highly invasive due to the use of a large incision (sternotomy) and cardiopulmonary&#xD;
      bypass (CPB), MIDCAB limits invasiveness by operating through a small incision (thoracotomy)&#xD;
      and by operating on the beating heart to avoid the need for CPB . By limiting invasiveness in&#xD;
      these ways, MIDCAB can reduce the risk of complications such as infection and stroke . In&#xD;
      comparison to traditional CABG and off-pump CABG (via a sternotomy), MIDCAB can enhance early&#xD;
      post-operative quality of life and recovery time . Minimally invasive multivessel coronary&#xD;
      surgery-coronary artery bypass grafting (MICS-CABG) through a small thoracotomy has many&#xD;
      advantages over minimally invasive direct coronary artery bypass (MIDCAB). First, MIDCAB is&#xD;
      limited to a single anastomosis of the left internal mammary artery to the left anterior&#xD;
      descending artery (LIMA-LAD). The surgical exposure of MICS-CABG is done more laterally,&#xD;
      leading to reduced risk of costochondral or rib injury. Also, MICS-CABG allows&#xD;
      revascularization with a similar configuration to that of a traditional sternotomy technique,&#xD;
      by direct-vision LIMA harvesting and hand-sewn proximal and distal anastomoses . MICS may be&#xD;
      performed with or without cardiopulmonary bypass (CPB) assistance, but the use of&#xD;
      femorofemoral CPB in multivessel revascularization has shown to be safe, mitigate the&#xD;
      learning curve, prevent conversions, and allows operative time like that of a sternotomy. ].&#xD;
      Other advantages include a diminished need for blood transfusion, decreased surgical site&#xD;
      infection rates, also early return to full physical function .&#xD;
&#xD;
      On the other hand complications include sternotomy conversion and development of left-sided&#xD;
      pleural effusion . Postoperative pain can be an issue early, but it is transient,&#xD;
      controllable, and significantly decreased by the third postoperative day; it is also&#xD;
      associated with an overall improved postoperative pain picture with improved pulmonary&#xD;
      functions . However, unlike sternotomy patients, MICS-CABG patients have no physical&#xD;
      restriction postoperatively, which leads to better independence.&#xD;
&#xD;
      This study aim to evaluate Safety and efficacy of multivessel minimally invasive coronary&#xD;
      artery bypass graft surgery through measuring several factors such as&#xD;
&#xD;
        1. measuring rate of intraoperative complications occurrence&#xD;
&#xD;
        2. measuring rate of intraoperative conversion to open sternotomy&#xD;
&#xD;
        3. measuring amount of post operative bleeding&#xD;
&#xD;
        4. measuring post operative pain&#xD;
&#xD;
        5. measuring rate of reexploration&#xD;
&#xD;
        6. measuring rate of wound infection&#xD;
&#xD;
        7. calculating days of postoperative hospital stay&#xD;
&#xD;
        8. calculating time to regain normal activity&#xD;
&#xD;
      The information gathered from the eligible patients will be entered into a data sheet&#xD;
      containing the variables of interest that will be analyzed later at the end of the study.&#xD;
      This study will not alter the patients' treatment and follow up at our center, by any means.&#xD;
&#xD;
      The following variables will be studied whenever applicable and whenever they are available&#xD;
      in the patients' charts:&#xD;
&#xD;
        1. Demographic data: (Medical Record Number ,Sex ,Age Other comorbidity)&#xD;
&#xD;
        2. Preoperative variables : (chest pain , dyspnea ,ECG findings ,Myocardial markers and&#xD;
           cardiac troponin ,Cardiac Angiography )&#xD;
&#xD;
        3. Operative variables: (Conversion to sternotomy. , Cardiac arrest ,Operation time ,Need&#xD;
           for IABP, CPB ,Need for blood transfusion)&#xD;
&#xD;
        4. Postoperative variables: (Mortality , Bleeding , Pain , Need of reexploration , Hospital&#xD;
           stay , Wound infection , Regain of normal activity , Relief of symptoms , Need for&#xD;
           another revascularization within 6 month)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measuring rate of intraoperative complications occurrence</measure>
    <time_frame>2 years</time_frame>
    <description>measuring the rate of complications as bleeding , failure of complete revascularization and cardiac arrest during operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measuring rate of intraoperative conversion to open sternotomy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>measuring amount of post operative bleeding</measure>
    <time_frame>2 years</time_frame>
    <description>measuring the amount of bleeding in the drains in 48 hours post operative in cc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measuring post operative pain</measure>
    <time_frame>2 years</time_frame>
    <description>measuring pain using wong-baker faces pain rating scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measuring rate of reexploration</measure>
    <time_frame>2 years</time_frame>
    <description>measuring the need of reexploration of the patient due to post operative massive bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measuring rate of wound infection</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>calculating days of postoperative hospital stay</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>calculating time to regain normal activity</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Minimal invasive coronary artery bypass graft</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>minimal invasive coronary artery bypass graft surgery</intervention_name>
    <description>coronary artery bypass grafting surgery by using a minimal invasive technique</description>
    <arm_group_label>Minimal invasive coronary artery bypass graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or more&#xD;
&#xD;
          2. Angiographically Indication for revascularization based upon symptoms of angina and/or&#xD;
             objective evidence of myocardial ischemia&#xD;
&#xD;
          3. Suitable minimally invasive coronary surgery (MICS) candidate for non-emergent first&#xD;
             time, single or multivessel coronary artery bypass grafting (on pump or off pump)&#xD;
&#xD;
          4. Willing and able to provide written informed consent and comply with study&#xD;
             requirements and accepting the need of conversion if needed.&#xD;
&#xD;
          5. Patient is willing to comply with all follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe congestive heart failure (class III or IV according to NYHA, or pulmonary&#xD;
             edema, cardiogenic shock) at the time of enrollment.&#xD;
&#xD;
          2. Prior surgery with the opening of pericardium or pleura.&#xD;
&#xD;
          3. Prior stroke (within 6 months)or more than 6 months if there are substantial&#xD;
             neurological defects.&#xD;
&#xD;
          4. Acute ST-elevation MI within 72 hours prior to enrollment requiring revascularization.&#xD;
&#xD;
          5. Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g.&#xD;
             valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stenting).&#xD;
&#xD;
          6. Contraindication to either CABG, MIDCAB or PCI/DES because of a coexisting clinical&#xD;
             condition.&#xD;
&#xD;
          7. Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding&#xD;
             diathesis.&#xD;
&#xD;
          8. Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine&#xD;
&#xD;
          9. Extra-cardiac illness that is expected to limit survival to less than 5 years e.g.&#xD;
             oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or&#xD;
             significant hepatic failure, severe renal disease.&#xD;
&#xD;
         10. Suspected pregnancy. A pregnancy test will be administered prerandomization to all&#xD;
             women of child-bearing age.&#xD;
&#xD;
         11. Patient inaccessible for follow-up visits required by protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>July 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Farouk Abdel Hafez</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

